Together, the partners will evaluate the application of a new approach for generating human pluripotent stem cell-derived macrophages for the treatment of acute and chronic bacterial pulmonary infections. The technology’s inventors include MHH scientists Prof. Dr Nico Lachmann, Dr Mania Ackermann and Dr Robert Zweigerdt.
Ascenion has been working with the MHH team for many years, supporting the validation, patenting and commercialization of their work. ‘I’m really grateful for the excellent support and outstanding commitment of Ascenion’s tech managers and legal experts, which made it possible to close the agreement by the end of 2020,’ says Nico Lachmann.
Jacob Sten Petersen, Corporate Vice President Stem Cell R&D of Novo Nordisk adds: ‘My team at Novo Nordisk’s Stem Cell R&D and I are very much looking forward to collaborating with the best scientists in the field, for the benefit of people with lung diseases.’
For further information see MHH's press release.